Psilocybin for Obsessive-Compulsive Disorder
BK
Overseen byBenjamin Kelmendi, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Yale University
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
This trial tests psilocybin from 'magic mushrooms' on patients with OCD who don't respond well to usual treatments. It aims to see if psilocybin can improve symptoms by helping 'reset' brain connections. Psilocybin has shown promising results in treating various psychiatric disorders, including depression, anxiety, and substance use disorders.
Research Team
CP
Christopher Pittenger, MD, PhD
Principal Investigator
Yale University
BK
Benjamin Kelmendi, MD
Principal Investigator
Yale University
Eligibility Criteria
This trial is for adults with Obsessive-Compulsive Disorder (OCD) who have tried at least one standard treatment without success. Participants must not be taking certain psychiatric medications, including SSRIs, and should have a support person available. They cannot join if they have a history of certain mental disorders, recent psychedelic use, or conditions that make MRI scans unsafe.Inclusion Criteria
You have a score of 18 or more on the YBOCS evaluation, which measures the severity of obsessive-compulsive disorder symptoms.
Willingness to sign a medical release for direct communication between research staff and external provider(s) about the participant's treatment and medical histories
I haven't taken SSRIs for at least 8 weeks.
See 18 more
Exclusion Criteria
You have Obsessive-Compulsive Personality Disorder (OCPD) or Borderline Personality Disorder (BPD).
I do not have uncontrolled diabetes, high blood pressure, heart issues, or a history of seizures or severe headaches.
You are currently feeling extremely sad or hopeless and have thoughts of wanting to harm yourself.
See 7 more
Treatment Details
Interventions
- Niacin (Vitamin)
- Psilocybin (Psychedelic)
Trial OverviewThe study tests the impact of psilocybin on OCD symptoms compared to niacin as a placebo. It's double-blind, meaning neither participants nor researchers know who gets the real drug versus placebo during the trial. The goal is to understand how psilocybin might affect brain function related to OCD.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PsilocybinExperimental Treatment1 Intervention
Psilocybin (0.25mg/kg)
Group II: NiacinPlacebo Group1 Intervention
Niacin (250mg)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Trials
1,963
Recruited
3,046,000+
National Institute of Mental Health (NIMH)
Collaborator
Trials
3,007
Recruited
2,852,000+
Heffter Research Institute
Collaborator
Trials
15
Recruited
520+